FATE Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

424B5Nov. 12, 2026, 5:21 p.m. ETView on SEC.gov
SCHEDULE 13D/ANov. 9, 2026, 7:08 p.m. ETView on SEC.gov
424B5Nov. 5, 2026, 4:36 p.m. ETView on SEC.gov
8-KNov. 5, 2026, 4:11 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Termination of a material definitive agreement · Financial statements and exhibits
AI summary, unreviewedFate Therapeutics Enters $100.0 Million At-the-Market Stock Sale Agreement With Leerink Partners, Terminates Jefferies ATM
10-QNov. 5, 2026, 7:07 a.m. ETView on SEC.gov
8-KNov. 5, 2026, 7:04 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedFate Therapeutics Q3 2026 EPS of -$0.25 Beats $0.26 Loss Estimate, but Revenue Falls to Zero; Cash Declines to $139.1 Million
4Nov. 4, 2026, 4:01 p.m. ETView on SEC.gov
8-KSept. 28, 2026, 8:10 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
10-QAug. 13, 2026, 8:34 a.m. ETView on SEC.gov
8-KAug. 13, 2026, 8:31 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
4Aug. 5, 2026, 4:03 p.m. ETView on SEC.gov
4Aug. 5, 2026, 4:01 p.m. ETView on SEC.gov